Neurology · Anticonvulsant
Teva's approval for a generic version of Gabapentin introduces significant competition in the neurology market, potentially impacting pricing and market share for existing branded products. Portfolio teams must evaluate the implications for their Gabapentin offerings and adjust strategies accordingly.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 8/3/2026, 6:04:03 AM
Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Teva's approval for a generic version of Gabapentin introduces significant competition in the neurology market, potentially impacting pricing and market share for existing branded products. Portfolio teams must evaluate the implications for their Gabapentin offerings and adjust strategies accordingly. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (10 high-relevance).
Portfolio teams should assess the impact of Teva's entry on market share and pricing strategies for Gabapentin products. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Neurology · Anticonvulsant, 7 regulatory and 4 competitive items passed relevance filtering for Teva.
The most relevant competitive pressure comes from Teva's Sugammadex Sodium Receives FDA Approval Status (Humanexa Signals) — entity match (teva). Secondary pressure from FDA Approves Sitagliptin and Metformin Hydrochloride Combination. This approval allows Teva to enter the market with a generic version of Gabapentin, increasing competition against branded products.
Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. While the approval itself is a positive regulatory development for Teva, it may prompt scrutiny and potential litigation from branded manufacturers concerned about market share erosion.
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — ZIAC (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View sourceUPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
MHRAhigh relevance
Entity match (gabapentin)
FDA document
View sourceThe Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMenstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceDynamic Auditory Cueing for Spatial Neglect in Stroke
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePhysical and Behavioral Traits of Overweight and Obese Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTeva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalshigh relevance
Entity match (teva)
FDA Approves Sitagliptin and Metformin Hydrochloride Combination
Humanexa Signalshigh relevance
Entity match (branded competitors)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceSandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisTeva's approval for a generic version of Gabapentin introduces significant competition in the neurology market, potentially impacting pricing and market share for existing branded products. Portfolio teams must evaluate the implications for their Gabapentin offerings and adjust strategies accordingly.
The entry of Teva's generic Gabapentin is likely to drive down prices and affect revenue streams for branded competitors, altering market dynamics significantly.
While the approval itself is a positive regulatory development for Teva, it may prompt scrutiny and potential litigation from branded manufacturers concerned about market share erosion.
Monitor market response and sales performance of Teva's Gabapentin as well as any potential litigation from branded competitors.
Track for follow-up milestones; no immediate action required.